ACG, a global supplier to the pharmaceutical and nutraceutical industries, has signed an MoU with the Government of Maharashtra to set up Asia’s largest manufacturing plant R&D center at Aurangabad in Maharashtra, to produce 40 billion capsules a year. The plant will serve both Indian and international pharmaceutical and nutraceutical companies.
 
Karan Singh, Managing Director, ACG, said, “Our vision to be a future-ready solutions provider to the pharma industry anywhere in the world and our proposed investment of approximately $100 million in this state-of-the-art plant, is an integral part of ACG’s mission to double our capsule manufacturing capacity to 240 billion capsules a year. This plant will play a key role in further cementing India’s position as the global hub of capsule manufacturing and will add to improved access to high quality, safe and affordable medicines and nutraceuticals globally.”
 
The proposed plant is part of ACG’s mission to ‘Make it better’ by providing exceptional solutions to produce the best and safest medicines to its customers, and enable access and affordable healthcare to all.
 
The plant will employ key design principles from the internationally recognized Leadership in Energy and Environmental Design (LEED) and will be powered significantly by green renewable energy to create and sustain value. It will employ automation and industry 4.0 technologies to minimize resource intensity and ensure products meet and exceed the highest global manufacturing practices (GMP).